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Abstract	  Matricellular	   proteins	   influence	  wide-­‐ranging	   fundamental	   cellular	   processes	   including	   cell	   adhesion,	  migration,	   growth	   and	   differentiation.	   	   They	   achieve	   this	   through	   both	   interactions	  with	   cell	   surface	  receptors	   and	   regulation	   of	   the	  matrix	   environment.	  Many	  matricellular	   proteins	   are	   also	   associated	  with	   diverse	   clinical	   disorders	   including	   cancer	   and	   diabetes.	   	   Alternative	   splicing	   is	   a	   precisely	  regulated	   process	   that	   can	   produce	  multiple	   isoforms	  with	   variable	   functions	   from	   a	   single	   gene.	   To	  date,	   the	  expression	  of	   alternate	   transcripts	   for	   the	  matricellular	   family	  has	  been	   reported	   for	  only	  a	  handful	  of	  genes.	  	  Here	  we	  analyse	  the	  evidence	  for	  alternative	  splicing	  across	  the	  matricellular	  family	  including	  the	  SPARC,	  thrombospondin,	  tenascin	  and	  CCN	  families.	   	  We	  find	  that	  matricellular	  proteins	  have	  double	  the	  average	  number	  of	  splice	  variants	  per	  gene,	  and	  discuss	  the	  types	  of	  domain	  affected	  by	  splicing	  in	  matricellular	  proteins.	  We	  also	  review	  the	  clinical	  significance	  of	  alternative	  splicing	  for	  three	  specific	  matricellular	  proteins	  that	  have	  been	  relatively	  well	  characterised:	  osteopontin,	  tenascin-­‐C	   and	   periostin.	   	   Embracing	   the	   complexity	   of	   matricellular	   splice	   variants	   will	   be	   important	   for	  understanding	   the	   sometimes	   contradictory	   function	   of	   these	   powerful	   regulatory	   proteins,	   and	   for	  their	  effective	  clinical	  application	  as	  biomarkers	  and	  therapeutic	  targets.	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  (POSTN).	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Introduction	  The	  extracellular	  matrix	  (ECM)	   is	  a	  protein	  scaffold	   that	  provides	  structural	  support	   to	   tissues,	  but	   is	  also	  increasingly	  recognised	  for	  the	  role	  it	  plays	  in	  providing	  context	  to	  the	  cell’s	  physical	  and	  chemical	  environment	  [1].	  The	  matrix	  activates	  specific	  cellular	  signalling	  pathways	  through	  binding	  of	  integrins	  and	  discoidin	  domain	  receptors	  (DDRs),	  for	  example.	  	  The	  synergy	  between	  integrin	  and	  growth	  factor	  signalling	   pathways	   further	   regulates	   cellular	   responses	   [2].	   In	   addition,	   the	   matrix	   can	   sequester	  cytokines	   and	   growth	   factors	   to	   achieve	   high	   local	   concentrations	   protected	   from	   degradation,	   and	  regulate	  the	  activation	  and	  release	  of	  growth	  factors	  [3].	  	  The	  physical	  properties	  of	  the	  matrix	  such	  as	  rigidity	   and	   tension	   control	   mechanosensory	   pathways	   essential	   for	   correct	   growth,	   migration	   and	  differentiation	   [2].	   	   	   The	  matrix	   is	   also	   capable	   of	   remodelling	   to	  mediate	   repair	   and	   to	   regulate	   cell	  growth,	  migration	   and	   differentiation	   [4].	   The	   distinct	  matrix	   composition	   of	   individual	   tissues	   is	   an	  important	  variable	  determining	  tissue-­‐specific	  characteristics,	  but	  as	  yet	  remains	  relatively	  undefined.	  	  Matricellular	   proteins	   are	   an	   important	   component	   of	   the	   extracellular	   matrix.	   Examples	   of	  matricellular	   proteins	   include	   the	   SPARC	   family,	   thrombospondins,	   tenascins,	   osteopontin,	   the	   CCN	  family	   and	   periostin.	   	   Although	   distinguished	   from	   structural	   matrix	   proteins	   such	   as	   collagen	   they	  nevertheless	  play	  an	  essential	  regulatory	  role,	  and	  are	  typically	  induced	  during	  tissue	  remodelling	  and	  repair	  as	  well	  as	  in	  many	  disease	  states	  [5].	  	  Matricellular	  proteins	  can	  influence	  matrix	  formation.	  	  	  For	  example,	   SPARC	  binds	   to	   structural	  matrix	   components	   such	   as	   collagen	   and	   fibronectin,	   and	   SPARC	  null	   mice	   have	   defective	   ECM	   that	   results	   in	   cataracts	   and	   allows	   increased	   tumour	   growth	   [6-­‐8].	  Collagen	  fibril	  formation	  during	  the	  foreign	  body	  response	  is	  also	  affected	  in	  SPARC	  null	  mice,	  as	  well	  as	  in	  mice	  lacking	  TSP-­‐1	  or	  TSP-­‐2	  [9].	  	  	  Matricellular	  proteins	  also	  modulate	  cellular	  responses	  to	  extracellular	  signals	  [10].	  Many	  matricellular	  proteins	  interact	  with	  both	  growth	  factors	  and	  integrins	  to	  regulate	  cell	  growth,	  adhesion	  and	  motility.	  	  For	  example,	  TSP-­‐1	   is	  a	  physiologically	  relevant	  activator	  of	  TGFβ:	   it	  binds	  to	   latent	  TGFβ	  via	  specific	  sequences	   in	   the	   thrombospondin	   repeat	   region,	   and	   causes	   a	   conformational	   change	   that	   activates	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TGFβ	   [11,12].	  TSP-­‐1	   can	   also	   transactivate	  EGFR	  and	   is	   involved	   in	   the	   regulation	  of	  VEGF,	   FGF,	   and	  PDGF	   signalling	   [12].	   Tenascin-­‐X	   was	   also	   recently	   identified	   as	   an	   activator	   of	   TGFβ	   [13].	   	   SPARC	  similarly	   regulates	   signalling	   by	   a	   number	   of	   growth	   factors,	   both	   directly	   and	   indirectly,	   including	  TGFβ,	   VEGF,	   PDGF,	   FGF	   and	   HGF	   [14,15].	   	   TGFβ	   in	   turn	   regulates	   the	   expression	   of	   a	   number	   of	  matricellular	  proteins,	  including	  SPARC,	  CCN1,	  TSP-­‐1,	  TSP-­‐2	  and	  periostin	  [16-­‐19].	  	  In	  terms	  of	  integrin	  binding,	  most	  matricelllar	  proteins	  bind	  to	  multiple	  integrin	  receptors,	  for	  example,	  SPARC,	   CCN1,	   OPN,	   periostin	   and	   fibulin-­‐5	   [5].	  Matricellular	   proteins	   can	   therefore	   directly	   regulate	  cell-­‐matrix	   interactions	   with	   subsequent	   effects	   on	   cell	   adhesion	   and	   migration.	   	   The	   capacity	   of	  matricellular	  proteins	   to	  modulate	   integrin	   signalling	  also	  allows	   indirect	   regulation	  of	  growth	   factor	  signalling	  through	  the	  intersection	  of	  these	  pathways.	   	  Although	  we	  still	  have	  much	  to	  learn	  about	  the	  effects	   of	   matricellular	   proteins	   in	   regulating	   cell	   responses	   to	   structural	   matrix	   proteins,	   some	  interesting	   illustrations	   are	   emerging.	   For	   example,	   TSP-­‐1	   binding	   to	   fibronectin	   regulates	   the	  interaction	   of	   TSP-­‐1	  with	   integrin	   α3β1	   [20].	   	   Along	   similar	   lines,	   studies	   identifying	   the	   location	   of	  SPARC	  binding	  on	  fibrillar	  collagen	  suggest	  that	  SPARC	  may	  influence	  the	  interaction	  between	  collagen	  and	  integrins,	  and	  potentially	  also	  collagen	  interactions	  with	  DDR2	  proteins	  [21].	  	  Matricellular	  proteins	  such	  as	  SPARC	  and	  TSP-­‐1	  were	  originally	  defined	  by	  their	  de-­‐adhesive	  properties	  	  	  [22],	  although	  more	  recently	  added	  members	  such	  as	  osteopontin	  and	  TSP2	  are	  now	  known	  to	  promote	  cell	  adhesion	  [10].	  	  Although	  in	  many	  cases	  the	  effects	  of	  matricellular	  proteins	  on	  cell	  adhesion	  relate	  to	  integrin	  binding,	  the	  effects	  of	  TSP-­‐2	  on	  cell	  adhesion	  are	  thought	  to	  be	  mediated	  by	  MMP	  regulation,	  though	   altered	  matrix	   and	   growth	   factor	   interactions	  may	   also	   play	   a	   role	   [10].	   	  Many	  matricellular	  proteins	  in	  fact	  regulate	  MMPs,	  for	  example	  the	  SPOCK	  family	  of	  proteins	  exhibit	  a	  complex	  regulation	  of	   MMP	   activity	   [23]	   and	   SPARC	   can	   upregulate	   expression	   of	   multiple	   MMPs	   in	   cancer	   cells	   [24].	  Through	   MMP	   regulation	   matricellular	   proteins	   can	   further	   influence	   not	   just	   cell	   adhesion	   and	  migration	  but	  also	  cell	  growth,	  since	  MMPs	  can	  activate	  and	  release	  growth	  factors	  such	  as	  VEGF	  and	  TGFβ	  [25].	  Interestingly,	  many	  matricellular	  proteins	  are	  also	  substrates	  of	  MMPs	  and	  other	  proteases,	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and	   cleavage	   of	   matricellular	   proteins	   can	   expose	   new	   active	   domains	   and	   binding	   sites,	   or	   disrupt	  existing	  motifs	  [26,27].	  As	  an	  illustration,	  thrombin	  cleavage	  of	  osteopontin	  reveals	  a	  cryptic	  non-­‐RGD	  epitope	  for	  integrin	  binding	  [28],	  and	  cleavage	  of	  SPARC	  produces	  fragments	  with	  increased	  affinity	  for	  collagen	  [21].	   	  Furthermore,	  cleavage	  of	  Hevin/SPARCL1	  by	  MMP3	  generates	  a	  “SPARC-­‐like	  fragment”	  associated	  with	  neovascularisation	  in	  glioma	  and	  that	  may	  compensate	  for	  loss	  of	  SPARC	  expression	  in	  some	   tissues	   [29,30].	   	   Matricellular	   proteins	   also	   regulate	   protease	   activity	   more	   widely	   than	   just	  MMPs,	   for	   example,	   CCN1	   inhibits	   ADAMTS4	   activity	   [19].	   This	   highly	   complex	   web	   of	   interactions	  between	  different	  matricellular	  proteins	  and	  other	  regulatory	  matrix	  components	  reinforces	  the	  inter-­‐connectedness	  underpinning	  homeostatic	  regulation	  of	  the	  matrix	  environment.	  	  	  	  Through	   both	   interactions	   with	   cell	   surface	   receptors	   and	   regulation	   of	   the	   matrix	   environment,	  matricellular	   proteins	   are	   therefore	   able	   to	   influence	   wide-­‐ranging	   fundamental	   cellular	   processes	  including	  cell	  adhesion,	  migration,	  growth	  and	  differentiation.	  	  There	  is	  a	  correspondingly	  large	  body	  of	  literature	   demonstrating	   the	   involvement	   of	   matricellular	   proteins	   in	   many	   and	   varied	   human	  disorders	   such	   as	   cancer,	   diabetes,	   cardiovascular	   disease	   and	   ocular	   disorders.	   	   For	   example,	  Osteopontin	   is	   over-­‐expressed	   in	   the	   stroma	   of	   a	   variety	   of	   cancers	   and	   increases	   malignancy	   and	  metastasis	   both	   in	   vivo	   and	   vitro	   [31].	   	   High	   levels	   of	   SPARC	   expression	   in	   the	   tumour-­‐stroma	   are	  similarly	   associated	   with	   disease	   progression	   in	   many	   cancers,	   including	   pancreatic	   cancer	   [4].	  However,	   in	   other	   types	   of	   cancer,	   such	   as	   ovarian	   and	   prostate	   cancers,	   SPARC	   expression	   is	  downregulated	   [32].	   This	   complexity	   is	   also	   reflected	   functionally,	   since	   although	   SPARC	   is	  overexpressed	  by	   the	  pancreatic	   tumour	   stroma,	   SPARC	  has	  been	   shown	   to	   inhibit	  pancreatic	   cancer	  cell	   growth	   in	   vitro	   [33].	   Similar	   contradictions	   are	   observed	   with	   CCN2:	   while	   poor	   prognosis	   is	  associated	  with	  low	  CCN2	  expression	  in	  breast	  cancer	  [34],	  poor	  prognosis	  is	  associated	  with	  increased	  expression	  in	  pancreatic	  cancer	  [35]	  and	  chondrosarcomas	  [36].	  	  	  	  Increased	  levels	  of	  SPARC	  are	  also	  associated	  with	  type	  2	  diabetes,	  obesity	  and	  insulin	  resistance,	  both	  in	  serum	  and	   in	  adipose	  tissue	  [37].	   	  SPARC	  expression	   is	  regulated	  by	  metabolic	  parameters	  such	  as	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insulin	  and	  glucose	  in	  both	  adipose	  tissue	  and	  in	  pancreatic	  stellate	  cells	  [15,37].	  	  Increased	  expression	  of	   SPARC	   is	   likely	   to	   have	   negative	   effects	   in	   the	   pancreas,	   since	   SPARC	   inhibits	   β	   cell	   responses	   to	  growth	  factors	  and	  inhibits	  β	  cell	  survival	  [15].	  However,	  it	  has	  also	  been	  suggested	  that	  ectopic	  SPARC	  expression	   in	   β	   cells	   can	   actually	   promote	   insulin	   secretion	   at	   high	   levels	   of	   glucose	   [38],	   perhaps	  consistent	   with	   the	   regulation	   of	   insulin	   release	   by	   integrin	   signalling	   [39].	   Therefore	   while	   the	  majority	  of	  evidence	  suggests	  a	  pathogenic	  role	   for	  SPARC	   in	  diabetes,	   it	  remains	  possible	   that	  under	  some	   circumstances	   SPARC	  may	  have	  beneficial	   effects	   in	  β	   cells.	   Similarly,	   TSP-­‐1	   expression	   in	   islet	  endothelial	  cells	  is	  important	  for	  islet	  function	  [40],	  and	  metabolic	  parameters	  such	  as	  high	  glucose	  also	  regulate	  TSP-­‐1	  expression	  [41].	  As	  for	  SPARC,	  elevated	  adipose	  expression	  of	  osteopontin	  also	  occurs	  in	  obesity,	  and	  is	  thought	  to	  predispose	  to	  insulin	  resistance	  [42].	  Interestingly,	  osteopontin	  expression	  is	  also	  increased	  in	  type	  1	  diabetes	  patients	  [43].	  	  Furthermore,	  the	  regulation	  of	  TGF-­‐β	  and	  other	  growth	  factors	  by	  SPARC,	  osteopontin,	  TSP-­‐1,	  and	  members	  of	  the	  CCN	  family	  have	  all	  been	  linked	  with	  diabetic	  complications	  such	  as	  nephropathy	  and	  retinopathy	  [44-­‐47].	  	  	  The	   contradictory	   effects	   of	   matricellular	   proteins	   can	   therefore	   be	   seen	   at	   both	   the	   functional	   and	  clinical	  level,	  as	  illustrated	  above	  for	  the	  tissue-­‐specific	  effects	  of	  proteins	  such	  as	  SPARC.	  The	  specific	  molecular	  mechanisms	  underlying	  this	  context	  dependence	  are	  almost	  entirely	  unknown,	  yet	  this	  must	  be	  addressed	  if	  we	  are	  to	  harness	  the	  potential	  therapeutic	  value	  of	  these	  powerful	  regulatory	  proteins.	  	  A	  number	  of	  matricellular	  proteins	  are	  currently	  involved	  in	  clinical	  trials	  [5,48],	  and	  it	  will	  therefore	  be	  important	  that	  we	  better	  understand	  mechanisms	  behind	  their	  controversial	  effects.	  	  	  The	   complexity	   in	   both	   form	   and	   function	   of	   matricellular	   proteins	   is	   likely	   to	   explain	   many	   of	   the	  controversies	   and	   tissue-­‐specific	   effects.	   Specific	   matricellular	   proteins	   are	   frequently	   observed	   at	   a	  range	   of	   different	   molecular	   weights,	   as	   revealed	   for	   example	   by	   western	   blotting.	   	   The	   multiple	  isoforms	  of	  these	  proteins	  are	  likely	  to	  result	  from	  a	  number	  of	  factors,	  including	  proteolytic	  cleavage	  as	   discussed	   above.	   Matricellular	   proteins	   are	   also	   subject	   to	   a	   range	   of	   post-­‐translational	  modifications,	   including	   glycosylation,	   phosphorylation	   and	   transglutaminase-­‐mediated	   crosslinking.	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Where	  multiple	  isoforms	  with	  different	  forms	  or	  degrees	  of	  post-­‐translational	  modification	  are	  present,	  these	   isoforms	   are	   likely	   to	   have	   distinct	   functions.	   	   For	   example,	   transglutaminase	   cross-­‐linking	   of	  osteopontin	  [49]	  and	  tissue-­‐specific	  glycosylation	  of	  SPARC	  both	  result	   in	  differential	  collagen	  affinity	  [21].	  	  	  Alternative	   splicing	   also	   is	   also	   likely	   to	   contribute	   to	  matricellular	   protein	   diversity.	   	   However,	   the	  expression	  of	  alternate	  transcripts	  for	  the	  matricellular	  family	  has	  been	  reported	  for	  only	  a	  handful	  of	  genes	  [5].	  In	  this	  review	  we	  will	  examine	  for	  the	  first	  time	  the	  evidence	  for	  alternative	  splicing	  across	  the	   matricellular	   family,	   highlighting	   specific	   areas	   for	   further	   study.	   	   We	   also	   illustrate	   the	   clinical	  significance	   of	   alternative	   splicing	   for	   three	   specific	   matricellular	   proteins	   for	   which	   splice	   variants	  have	  been	  relatively	  well-­‐characterised:	  osteopontin,	  tenascin-­‐C	  and	  periostin.	  	  
Overview	  of	  splice	  variation	  in	  matricellular	  proteins	  Alternative	  splicing	   is	  a	  precisely	   regulated	  process	   that	  can	  produce	  multiple	   isoforms	  with	  variable	  functions	  from	  a	  single	  gene.	  Alternative	  splicing	  is	  tissue	  dependent	  and	  is	  regulated	  by	  tissue	  specific	  
cis-­	  and	  trans-­‐	  splicing	  activators	  that	  influence	  spliceosome	  assembly	  [50].	  	  We	  performed	  an	  analysis	  of	   the	  splice	  variants	   identified	   in	   the	  ENSEMBL	  database	   for	  22	  matricellular	  proteins,	   including	   the	  SPARC,	  thrombospondin,	  tenascin	  and	  CCN	  families,	  as	  well	  as	  osteopontin	  and	  periostin.	  	  As	  shown	  in	  Table	  1,	  the	  number	  of	  splice	  variants	  listed	  ranges	  from	  1	  to	  26,	  with	  a	  mean	  of	  8	  variants	  in	  the	  set	  of	  matricellular	   genes	   analysed	   (sd=5.3,	   n=22).	   	   Less	   than	   half	   of	   these	   are	   predicted	   by	   ENSEMBL	   to	  encode	   a	   potentially	   functional	   protein	   that	   would	   be	   not	   be	   degraded	   by	   cellular	   quality	   control	  mechanisms	   (100/276	   variants	   for	   all	   genes	   analysed).	   	   Many	   non-­‐coding	   transcripts	   have	   retained	  introns,	   and	   such	   transcripts	   are	   typically	   restricted	   to	   the	   nucleus	   and	   thought	   to	   be	   the	   result	   of	  splicing	   errors,	   although	   functionally	   relevant	   cases	   of	   transcripts	   with	   retained	   introns	   have	   been	  described	   [51].	   However,	   17	   protein	   coding	   variants	   are	   identified	   for	   SPOCK3,	   and	   10	   for	  
SPARCL1/Hevin.	  	  Other	  members	  of	  the	  SPARC	  family	  with	  relatively	  high	  numbers	  of	  variants	  listed	  are	  
SPARC	   and	   SPOCK1,	   with	   5	   predicted	   protein-­‐coding	   variants	   each.	   	   Other	   matricellular	   proteins	   of	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interest	  in	  this	  regard	  are	  tenascin	  C,	  tenascin	  XB	  and	  osteopontin,	  having	  8,	  6	  and	  5	  predicted	  protein	  variants,	  respectively.	  	  	  	  Recent	   estimates	   of	   the	   prevalence	   of	   alternatively	   spliced	   transcripts	   based	   on	   the	   ENCODE	  project	  suggest	  that,	  of	  the	  24,000	  genes	  in	  the	  human	  genome,	  92–97%	  express	  alternatively	  spliced	  variants,	  with	  an	  average	  of	  4	   isoforms	  per	  gene	  and	  on	  average	  2.5	  protein	  coding	  variants	  per	  gene	   [52,53].	  	  Matricellular	  proteins	  therefore	  have	  on	  average	  around	  double	  the	  average	  number	  of	  splice	  variants	  per	   gene,	   and	   double	   the	   number	   of	   protein	   coding	   variants	   per	   gene.	   	   As	   discussed	   below,	   there	   is	  growing	   evidence	   for	   the	   importance	   of	   splice	   variants	   of	   matricellular	   genes	   in	   human	   health	   and	  disease.	   	  However,	   there	   is	  clearly	  still	  much	  work	  to	  be	  done	  in	  this	  area.	   	  Of	  the	  matricellular	  genes	  analysed	   here,	   only	   72/100	   protein	   coding	   variants	   listed	   in	   ENSEMBL	   contain	   the	   complete	   coding	  sequence	  (CDS),	  and	  this	  is	  a	  particular	  problem	  for	  some	  members	  of	  the	  SPARC	  family.	  	  For	  example,	  
SPARC	   (1/5	   complete	   CDS),	   SPARCL1	   (3/10	   complete	   CDS)	   and	   SPOCK1	   (2/5	   complete	   CDS).	  	  Furthermore,	   less	   than	   40%	   of	   the	   protein-­‐coding	   variants	   have	   a	   high	   support	   level,	   classified	   by	  ENSEMBL	  as	   transcript	   support	   level	  1	   (TSL1).	   	  TSL1	   indicates	   that	   the	   transcript	   is	   supported	  by	  at	  least	  one	  non-­‐suspect	  mRNA	  [54].	   	  Transcripts	  with	  support	  lower	  than	  TSL1	  are	  typically	  based	  only	  on	  either	  one	  or	  more	  EST	  sequences,	  or	  on	  a	  suspect	  mRNA	  sequence,	  or	  are	  not	  supported	  by	  either	  an	  EST	   or	  mRNA	   sequence	   (TSL5).	   	   Further	  work	  will	   therefore	   be	   required	   to	   identify	   and	   validate	  predicted	  variants	  of	  these	  matricellular	  proteins,	  in	  particular	  the	  SPARC	  family.	  	  	  	  One	  critical	  question	  will	  be	  to	  determine	  the	  abundance	  of	  these	  matricellular	  splice	  variants.	  	  There	  is	  evidence	   that	  many	   splice	   variants	   identified	   by	  high	   throughput	  methods	   are	   at	   low	   frequency,	   and	  that	   these	   low	   frequency	   variants	   are	   typically	   not	   evolutionarily	   conserved	   and	   therefore	   of	  questionable	   functional	   significance	   [55].	   	   Furthermore,	   it	   has	   been	   estimated	   that	   around	   80%	   of	  transcripts	   in	   human	   tissue	   represent	   the	   major	   isoform,	   suggesting	   relatively	   minor	   roles	   for	  alternative	   splice	   variants	   in	   most	   cases	   [51].	   	   However,	   the	   number	   of	   variants	   identified	   for	  matricellular	  genes	  suggests	  that	  many	  matricellular	  genes	  may	  be	  amongst	  the	  exceptions.	  	  Splicing	  is	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also	  altered	  in	  disease	  states	  such	  as	  cancer,	  and	  we	  discuss	  the	  evidence	  for	  the	  clinical	  importance	  of	  splice	  variants	  of	   three	  matricellular	   genes	  below.	   It	  will	   also	  be	   important	   to	  determine	   cell	   specific	  expression	  patterns	  of	  matricellular	  splice	  variant	  transcripts	  and	  their	  relative	  abundance	  in	  different	  tissues,	  and	  to	  gain	  insight	  into	  the	  factors	  that	  regulate	  their	  expression.	  	  While	  RNA	  seq	  data	  from	  the	  Illumina	  Body	  Map	  project,	  for	  example,	  can	  be	  accessed	  through	  ENSEMBL	  and	  provides	  tissue	  specific	  information	  on	  intron-­‐spanning	  sequencing	  reads,	  data	  for	  alternative	  transcript	  expression	  abundance	  in	  different	  cell/tissue	  types	  is	  currently	  not	  available.	   	  Splice	  variant	  databases	  are	  also	  not	  currently	  linked	   to	  high	   throughput	  proteomics	  data	  such	  as	  mass	  spectrometry.	   	  However,	   for	  coding	  variants	  where	  detailed	  structural	  and	  domain	  functional	  data	  is	  available	  for	  the	  primary	  isoform	  it	  is	  possible	  to	   use	   bioinformatics	   tools	   to	   make	   predictions	   about	   the	   function	   of	   alternatively	   spliced	   proteins,	  which	  can	  then	  be	  tested	  experimentally.	  	  	  While	   many	   of	   the	   matricellular	   splice	   variants	   collated	   in	   ENSEMBL	   predict	   a	   change	   in	   protein	  sequence,	  there	  is	  also	  striking	  splice	  variation	  in	  exons	  encoding	  5’-­‐	  and	  3’-­‐UTR	  regions	  of	  these	  genes.	  The	  potential	  importance	  of	  variation	  in	  the	  5’-­‐	  and	  3’-­‐UTRs	  should	  also	  not	  be	  underestimated,	  as	  our	  understanding	   grows	   of	   how	   the	   secondary	   structure	   of	   these	  UTR	   can	   affect	   transcript	   stability,	   for	  example	  by	  miRNA-­‐mediated	  degradation	  [56],	  and	  also	  regulate	  the	  translational	  machinery	  [57].	   	  In	  support	  of	  the	  importance	  of	  UTR	  regions	  in	  matricellular	  protein	  expression,	  TSP-­‐1	  in	  particular	  has	  a	  long	  3’UTR	   that	  has	  been	  analysed	   in	  detail,	   and	   is	  known	  to	  contain	  AU-­‐	  rich	  elements	   that	   regulate	  mRNA	   stability	   [17].	   	   Indeed,	   the	   regulation	   of	   TSP-­‐1	   expression	   by	   glucose	   occurs	   at	   the	   level	   of	  translation	   and	   is	   mediated	   by	   miR-­‐467	   binding	   to	   the	   3’-­‐UTR	   [58,59].	   	   SPARC	   expression	   is	   also	  regulated	  by	  non-­‐coding	  RNA,	  and	   in	  particular	   is	   regulated	  by	  miR029a/b	   in	  nasopharangeal	   cancer	  [60].	   	  The	  potential	   importance	  of	  UTR	  regions	  should	  therefore	  not	  be	  overlooked	  when	  considering	  variants	  affecting	  UTR	  rather	  than	  coding	  regions.	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Osteopontin	  splice	  variants	  –	  evidence	  for	  association	  with	  specific	  cancer	  types.	  Osteopontin	  is	  a	  member	  of	  the	  SIBLING	  family	  of	  glycoproteins	  and	  is	  expressed	  from	  the	  SPP1	  gene	  on	  human	  chromosome	  4.	  	  As	  show	  in	  Figure	  1,	  a	  total	  of	  6	  splice	  variants	  were	  identified	  across	  the	  two	  databases,	   and	   in	  Table	  2	  we	  have	   integrated	   the	   IDs	   for	   these	   splice	  variants	   in	  ENSEMBL,	  Genbank	  and	  the	  common	  names	  used	  in	  the	  literature.	  	  Three	  splice	  variants	  of	  OPN	  have	  been	  known	  for	  some	  time,	  widely	   referred	   to	   as	   OPN-­‐a,	   OPN-­‐b	   and	   OPN-­‐c	   in	   the	   literature,	   and	   have	   been	   relatively	  well	  characterised,	  while	  OPN-­‐4	  and	  OPN-­‐5	  were	  only	   very	   recently	   identified	   [61].	   	   Variant	  201	   listed	   in	  ENSEMBL	  has	  not	  been	  previously	  described	  and	  appears	  to	  affect	  exon	  7	  outside	  the	  splicing	  region,	  although	   this	   variant	   is	   listed	   as	   TSL-­‐2	   and	   remains	   to	   be	   confirmed.	   Interestingly,	   the	   recently	  described	  OPN-­‐5	   is	  now	   the	   longest	   transcript	   and	   therefore	   the	   reference	   sequence	  at	  NCBI,	   though	  this	  transcript	  is	  not	  listed	  in	  ENSEMBL.	  This	  unusual	  variant	  has	  an	  alternate	  transcriptional	  start	  site,	  and	  is	  discussed	  further	  below.	  	  	  The	   osteopontin	   (OPN)	   protein	   is	   relatively	   unstructured	   and	   lacks	   predicted	   domains	   identified	   by	  bioinformatics	   searches	   [62,63].	   However,	   the	   regions	   involved	   in	   ligand	   binding	   have	   been	  characterized,	  as	  indicated	  in	  Figure	  1A.	  	  There	  are	  three	  integrin-­‐binding	  motifs	  in	  the	  central	  region	  of	  the	  protein,	  plus	  a	  C-­‐terminal	  region	  responsible	  for	  CD44	  binding	  and	  containing	  an	  EF-­‐hand	  calcium	  binding	  motif	   [64].	   	  However,	   the	  N-­‐terminal	   region	  adjacent	   to	   the	  signal	  peptide	   that	   is	   affected	  by	  splicing	   lacks	   any	   known	   ligand	   binding	   domains	   [65],	   although	   this	   region	   does	   include	   O-­‐linked	  glycosylation	  and	  phosphorylation	  sites,	  and	  may	  also	  contain	  sites	  of	  interaction	  with	  the	  extracellular	  matrix	   [26].	   	   According	   to	   Anborgh	   et	   al,	   the	   exon	   labeled	   ‘exon	   5’	   in	   Figure	   1	   contains	   glutamine	  residues	   that	  undergo	   cross-­‐linking	  by	   transglutaminase	   [31].	  This	   exon	   is	   absent	   in	  both	  OPN-­‐c	   and	  OPN-­‐4	  variants,	  suggesting	  that	  these	  variants	  may	  be	  unable	  to	  form	  polymeric	  structures	  (Table	  2	  and	  Figure	  1).	  Cross-­‐linking	  enhances	  the	  ability	  of	  osteopontin	  to	  bind	  collagen	  [49],	  suggesting	  that	  OPN-­‐c	  and	  OPN-­‐4	  may	  have	  reduced	  collagen	  binding.	   	  Furthermore,	   the	  alternatively	  spliced	  exons	  5	  and	  6	  contain	  putative	  phosphorylation	  sites	  (exon	  numbering	  as	   indicated	   in	  Figure	  1),	  suggesting	  that	  the	  various	   splice	   variants	   identified	  will	   contain	   distinct	   phosphorylation	  patterns	   [66].	   	   The	   binding	   of	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osteopontin	   to	   integrins	   is	  known	   to	  be	   regulated	  by	  phosphorylation[67],	   and	   it	  has	  been	  suggested	  that	   OPN-­‐a	   and	   OPN-­‐b,	   but	   not	   OPN-­‐c,	   can	   activate	   integrin	   receptors	   [68].	   	   This	   would	   imply	   that	  phosphorylation	   of	   exon	   5	   determines	   integrin	   binding,	   though	   this	   would	   need	   experimental	  confirmation.	  	  There	  is	  also	  further	  evidence	  for	  functional	  and	  clinical	  diversity	  of	  these	  variants.	  	  While	  RNA	  seq	  data	  in	  ENSEMBL	  suggests	   that	  OPN-­‐a	   is	  expressed	   in	  all	   tissues	   tested	   (ENSEMBL	  accessed	  March	  2016),	  multiple	   splice	  variants	  of	  osteopontin	  are	   found	   in	   cancer	   cells.	   For	   example,	   in	   a	   study	  by	  He	  et	  al,	  OPN-­‐c	  was	  detected	   in	  breast	   cancer	  but	  not	  normal	   tissue,	  and	  OPN-­‐c	  over-­‐expression	  was	   found	   to	  promote	  breast	  cancer	  cell	  invasion	  in	  vitro.	  In	  contrast,	  OPN-­‐a	  promoted	  cell	  adhesion	  [65].	  A	  follow	  up	  study	   with	   increased	   number	   of	   patient	   samples	   found	   a	   more	   complex	   picture,	   but	   demonstrated	  strong	   association	   between	   nuclear	   OPN-­‐c	   and	  mortality	   in	   patients	   with	   early	   onset	   breast	   cancer,	  while	  expression	  of	  OPN-­‐a/b	  in	  the	  cytoplasm	  was	  associated	  with	  poor	  prognosis	  [69].	  	  In	  pancreatic	  cancer	   the	   picture	   is	   subtly	   different.	   	   While	   OPN-­‐a	   was	   found	   to	   be	   highly	   expressed,	   OPN-­‐c	   was	  associated	   with	   metastatic	   disease	   and	   OPN-­‐b	   expression	   showed	   a	   trend	   towards	   association	   with	  poor	  survival	  rates	  [70].	  Similarly,	  in	  gastric	  cancer	  and	  glioma	  while	  OPN-­‐a,	  OPN-­‐b	  and	  OPN-­‐c	  were	  all	  expressed,	   only	   OPN-­‐b	   and	   OPN-­‐c	   were	   associated	   with	   the	   severity	   of	   disease	   symptoms,	   and	   in	  particular	  OPN-­‐c	  was	  again	  found	  to	  be	  associated	  with	  metastasis	  [71-­‐73].	  	  In	  a	  study	  by	  Tilli	  et	  al,	  a	  mechanistic	  analysis	  helped	  to	  shed	  additional	  light	  on	  the	  effects	  of	  individual	  isoforms.	  	  Stable	  expression	  of	  OPN-­‐a,	  OPN-­‐b	  and	  OPN-­‐c	  variants	  in	  prostate	  cancer	  cells	  revealed	  that	  both	  OPN-­‐b	   and	  OPN-­‐c	   promote	   xenograft	   growth,	   as	  well	   as	   increasing	   proliferation,	  migration	   and	  invasion.	  	  Expression	  of	  OPN-­‐b	  and	  OPN-­‐c	  also	  increased	  expression	  of	  MMP-­‐2,	  MMP-­‐9	  and	  VEGF	  [74].	  	  In	  a	  similar	  study	  by	  Lin	  et	  al,	  stable	  expression	  of	  OPN-­‐b	  in	  esophageal	  carcinome	  (EAC)	  cells	  increased	  migration	   and	   enhanced	   invasion	   compared	   to	   cells	   expressing	   OPN-­‐c.	   	   However,	   OPN-­‐c	   expression	  dramatically	  reduced	  cell	  adhesion,	  and	  the	  authors	  suggest	  that	  OPN	  isoforms	  have	  distinct	  effects	  on	  cell	  behaviour	  but	  can	  work	  together	  to	  promote	  EAC	  progression	  (Lin,	  2015).	  	  This	  is	  consistent	  with	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the	  clinical	  evidence	  described	  above	  suggesting	  that	  both	  OPN-­‐b	  and	  OPN-­‐c	  are	  overexpressed	  in	  some	  cancers,	  for	  example	  pancreatic	  [70,75],	  gastric	  [71],	  lung	  [75],	  and	  prostate	  [74],	  while	  OPN-­‐c	  may	  be	  most	  strongly	  associated	  with	  other	  cancers,	  such	  as	  breast	  cancer	  [65,75,76]	  and	  ovarian	  cancer	  [77].	  	  	  These	  and	  other	  studies	  suggest	  the	  potential	  value	  of	  OPN	  isoforms	  as	  biomarkers	  for	  specific	  cancers.	  This	   idea	  was	   tested	   by	   Hartung	   and	  Weber	   in	   a	   study	   analysing	   blood	   serum	   from	   patients	  with	   a	  range	  of	  cancers	  using	  an	  OPN	  isoform	  specific	  RT-­‐PCR	  assay.	  	  Increased	  expression	  of	  both	  OPN-­‐b	  and	  OPN-­‐c	  was	  observed	  in	  the	  serum	  of	  pancreatic	  cancer	  patients	  while	  OPN-­‐c	  was	  elevated	  in	  the	  serum	  of	  lung	  as	  well	  as	  in	  breast	  cancers	  [75].	  OPN-­‐b	  was	  also	  elevated	  in	  the	  serum	  of	  lung	  cancer	  patients,	  and	  when	  a	  cutoff	  of	  2	  SD	  over	  normal	  was	  used,	  could	  detect	  over	  40%	  lung	  cancers.	  	  	  Diabetes	  is	   a	   risk	   factor	   for	   pancreatic	   cancer,	   and	   osteopontin	   expression	   is	   also	   increased	  in	  diabetes	  patients	   [78,79].	  	  Recently,	   Sarosiek	   et	   al	   examined	   the	   expression	   of	   specific	   osteopontin	  splice	   variants	   in	   patients	   with	   pancreatic	   lesions	   and	   with	  diabetes	  or	   obesity.	  	  In	   patients	   with	  pancreatic	   lesions,	  OPN-­‐b	  was	   found	   in	  48%	  of	   sera,	  OPN-­‐c	   in	  34%,	  and	  both	  variants	   in	  5%	  of	   sera;	  neither	   variant	   was	   detected	   in	   normal	   sera.	   However,	   in	   patients	   with	   pancreatic	   lesions	   who	   also	  had	  diabetes	  and/or	  obesity,	  OPN-­‐b	  was	  completely	  absent	  and	  the	   frequency	  of	  OPN-­‐c	  detection	  was	  significantly	   increased.	  Logistic	  regression	  modelling	  showed	  that	   the	  odds	  of	  having	  diabetes	  and/or	  obesity	   in	   a	   patient	   with	   OPN-­‐c	   were	   seven	   times	   higher	   than	   patients	   without	   OPN-­‐c.	  	  This	   study	  demonstrates	   an	   association	   between	   diabetes/obesity	   and	   OPN-­‐c	   expression,	   and	   suggests	   the	  possibility	   that	   osteopontin	   splice	   variants	   may	   be	   involved	   in	   the	   link	   between	   pancreatic	   cancer	  and	  diabetes/obesity	  [79].	  	  OPN-­‐5	   was	   recently	   described	   by	   Lin	   et	   al	   [61]	   and	   is	   now	   the	   longest	   transcript	   identified.	   	   As	  mentioned	   above,	   this	   variant	   has	   a	   unique	   additional	   exon	   (exon	   4)	   containing	   an	   alternative	  translation	  start	   site.	   	   Interestingly,	   since	   the	  signal	  peptide	   is	  encoded	  by	  exon	  2,	   the	  OPN-­‐5	  protein	  created	   using	   the	   downstream	   translation	   start	   site	   therefore	   lacks	   the	   signal	   peptide.	   	   The	   Phobius	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software	  for	  predicting	  signal	  peptides	  clearly	  identifies	  AA	  1-­‐16	  of	  the	  other	  osteopontin	  variants	  as	  a	  signal	  peptide,	  but	  does	  not	  identify	  a	  signal	  peptide	  sequence	  in	  OPN-­‐5	  [80],	  results	  that	  are	  confirmed	  using	   the	   SignalP	   prediction	   tool.	   	   It	   is	   therefore	   likely	   that	   OPN-­‐5	   encodes	   an	   intracellular	   isoform.	  	  Translation	  of	  the	  OPN-­‐5	  transcript	  using	  ExPASy	  indicates	  that	  the	  upstream	  start	  codon	  utilized	  by	  all	  other	  OPN	  isoforms	  creates	  an	  upstream	  open	  reading	  frame	  (uORF)	  in	  the	  OPN-­‐5	  transcript,	  due	  to	  the	  presence	  of	  an	  in-­‐frame	  stop	  codon,	  as	  illustrated	  in	  Figure	  1D.	  Only	  the	  downstream	  translational	  start	  site	   can	   therefore	   create	   a	   functional	   protein.	   	   Interestingly,	   uORF	   are	   important	   regulators	   of	  translation,	   particularly	   in	   response	   to	   nutritional	   and	   metabolic	   stress	   [81].	   The	   OPN-­‐5	   uORF	   may	  therefore	   serve	   to	   regulate	   the	   translational	   efficiency	   of	   the	  OPN-­‐5	   protein	   under	   certain	  metabolic	  conditions.	  	  	  	  Although	  matricellular	  proteins	  typically	  contain	  a	  signal	  peptide	  that	  targets	  the	  protein	  for	  secretion,	  and	   osteopontin	   is	   generally	   regarded	   as	   a	   secreted	   protein,	   osteopontin	   has	   been	   detected	  intracellularly.	   	   Nuclear	   localisation	   of	   OPN	   has	   been	   described	   [82]	   and	   an	   intracellar	   isoform	   of	  osteopontin	   (OPNi)	   has	   also	   been	   characterised.	   	   This	   intracellular	   form	   is	   a	   truncated	   protein	   that	  lacks	   the	   N-­‐terminus,	   including	   the	   signal	   peptide,	   and	   is	   instead	   localised	   to	   the	   cytoplasm.	  	  Interestingly,	  this	  protein	  was	  not	  thought	  to	  be	  a	  splice	  variant,	  but	  instead	  is	  thought	  to	  arise	  from	  the	  use	  of	  an	  alternate	  downstream	  translation	  start	  site	  [83],	  although	  other	  possibilities	  have	  also	  been	  discussed	   [28,84].	   	  OPNi	  has	  distinct	   functions	   to	   secreted	  OPN,	   and	   in	  particular	  plays	  an	   important	  role	   in	   innate	   immune	   cells,	   for	   example	   dendritic	   cells	   and	  NK	   cells	   [83,84],	  where	   it	   is	   involved	   in	  signalling	   transduction	   pathways	   downstream	   of	   innate	   immune	   receptors	   [28].	   It	   will	   therefore	   be	  interesting	  to	  test	  whether	  innate	  immune	  cells	  express	  the	  OPN-­‐5	  variant.	  	  	  The	  second	  splice	  variant	  recently	  described	  by	  Lin	  et	  al,	  OPN-­‐4,	  is	  the	  shortest	  transcript	  and	  lacks	  all	  the	  alternatively	   spliced	  exons	  4,	  5	   and	  6	   [61].	   	  This	   study	   found	   that	   all	   5	   characterised	   isoforms	  of	  OPN,	  including	  OPN-­‐4	  and	  OPN-­‐5,	  are	  co-­‐overexpressed	  in	  primary	  oesophageal	  cancer	  [61].	  	  However,	  no	  other	  studies	  have	  yet	  examined	  the	  function	  of	  OPN-­‐4	  and	  OPN-­‐5	  or	  their	  potential	  role	  in	  disease.	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  While	   the	   predicted	  molecular	  weight	   of	   the	   proteins	   encoded	   by	   the	   5	   identified	   osteopontin	   splice	  variants	   ranges	   from	   30.8	   kDa	   (OPN-­‐4)	   to	   37.2	   kDa	   (OPN-­‐5;	   predicted	  molecular	  weights	   calculated	  using	  Expasy),	  the	  primary	  observed	  band	  in	  western	  blotting	  is	  typically	  around	  70	  kDa,	  and	  multiple	  bands	   ranging	   from	   41	   to	   75	   kDa	   are	   frequently	   observed	   [31].	   	   However,	   osteopontin	   undergoes	  extensive	   post-­‐translational	   modification,	   with	   serine/threonine	   phosphorylation,	   glycosylation,	  tyrosine	   sulfation	   and	   cross-­‐linking,	   and	   osteopontin	   is	   also	   a	   substrate	   for	   thrombin	   and	   matrix	  metalloproteinases.	   	   The	   relationship	   between	   expression	   of	   particular	   splice	   variants	   and	   observed	  protein	  isoforms	  of	  different	  molecular	  weights	  is	  therefore	  complex	  and	  challenging	  to	  unravel.	  	  In	  summary,	  osteopontin	  mediates	  cell	  adhesion	  and	  regulates	  signalling	  by	  interacting	  with	  a	  range	  of	  binding	   partners	   such	   as	   CD44	   and	   integrins.	   There	   is	   evidence	   that	   alternative	   splicing	   creates	  isoforms	  with	  distinct	  post-­‐translational	  modifications	  that	  are	   likely	   to	  affect	   the	  capacity	   to	   interact	  with	   integrins	   and	   collagen.	   	   Expression	   of	   specific	   isoforms	   has	   been	   shown	   to	   be	   associated	   with	  diseases	  such	  as	  cancer	  and	  diabetes,	  though	  more	  recently	  described	  variants	  remain	  as	  yet	  relatively	  uncharacterised.	  Understanding	  the	  role	  of	   these	   isoforms	  and	  their	  expression	  has	  great	  potential	   in	  their	  use	  as	  biomarkers	  and	  therapeutic	  targets.	  	  	  
Tenascin-­C	  splice	  variants	  as	  therapeutic	  targets	  Tenascin-­‐C	   (TNC)	   is	   a	   large	  matricellular	   glycoprotein	   that	   forms	   a	   1080–1500	   kDa	   hexamer,	   and	   is	  encoded	   by	   the	   TNC	   gene	   on	   human	   chromosome	   9.	   	   Like	   many	   other	   matricellular	   proteins	   TNC	  expression	   is	  normally	   limited	   in	   the	  adult	  but	   is	  upregulated	  during	   tissue	   remodelling,	   for	  example	  during	  wound	  repair,	  inflammation	  and	  cancer.	  	  Indeed,	  increased	  expression	  of	  tenascin-­‐C	  by	  tumour-­‐stroma	   cells	   is	   associated	   with	   a	   wide	   range	   of	   cancers	   [85].	   	   Tenascin-­‐C	   modulates	   cell	   adhesion,	  migration,	  proliferation	  and	  survival	  [86],	  and	  there	  are	  ongoing	  clinical	  trials	  in	  which	  TNC	  is	  targeted	  for	  the	  treatment	  of	  various	  disorders	  including	  heart	  disease,	  inflammatory	  disease	  and	  cancer	  [86,87].	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There	   are	   20	   human	   TNC	   splice	   variants	   identified	   in	   the	   ENSEMBL	   and	   NCBI	   Gene	   databases	   (see	  Table	  3	   for	   further	  detail),	  and	   the	  exon	  structures	  of	   the	  subset	  of	  variants	  present	   in	  ENSEMBL	  are	  shown	   in	   Figure	   2B	   as	   an	   illustration.	   	   As	   shown	   in	   Figure	   2A,	   tenascin-­‐C	   contains	   a	   C-­‐terminal	  fibrinogen-­‐like	  globe	  (FBG)	  domain	  and	  a	  region	  towards	  the	  N-­‐terminus	  containing	  EGF-­‐like	  repeats.	  Tenascin-­‐C	   is	   a	   low	   affinity	   ligand	   for	   EGF	   receptor	   and	  binding	   is	  mediated	   by	   the	  EGF-­‐like	   repeats	  [88].	  	  The	  tenascin-­‐C	  protein	  also	  contains	  a	  central	  domain	  consisting	  of	  fibronectin	  type	  III-­‐like	  (FNIII)	  repeats	   that	   binds	   various	   integrin	   receptors	   and	   growth	   factors	   [85,89].	   	   Alternative	   splicing	  exclusively	  affects	  this	  central	  FNIII	  domain	  and	  determines	  the	  number	  of	  FNIII-­‐like	  repeat	  units.	  	  	  There	   is	   extensive	   evidence	   for	   functional	   diversity	   in	   alternative	   splice	   variants	   of	   tenascin-­‐C.	   This	  topic	  has	  been	  recently	  reviewed	  in	  detail	  [90]	  so	  only	  a	  brief	  overview	  is	  given	  here.	  TNC	  variants	  are	  typically	  divided	  into	  ‘long’	  and	  ‘short’	  variants,	  where	  long	  TNC	  variants	  can	  contain	  up	  to	  17	  FNIII	  like	  repeats.	   	  The	  small	  TNC	  variant,	  TNC-­‐S,	  (220	  kDa)	  binds	  to	  fibronectin,	  while	  the	  large	  variant,	  TNC-­‐L,	  (320	  kDa)	  does	  not	  [91].	  	  In	  contrast,	  it	  is	  uniquely	  the	  large	  TNC	  variants	  that	  bind	  with	  high	  affinity	  to	  annexin	   II	   [92,93].	   	   Furthermore,	   while	   short	   variants	   promote	   focal	   adhesion	   formation	   and	   cell	  adhesion,	   long	   variants	   typically	   inhibit	   the	   formation	   of	   focal	   adhesions	   and	  promote	   cell	  migration	  [94].	  These	  observations	  have	  been	   important	   for	   rationalising	  previous	  observations	   that	   tenascin-­‐C	  could	  either	  promote	  or	  inhibit	  cell	  adhesion,	  and	  are	  an	  excellent	  illustration	  of	  how	  the	  identification	  of	  alternative	  splice	  variants	  can	  resolve	  existing	  functional	  controversies.	  	  	  	  Interestingly,	  examination	  of	  the	  splice	  variants	  in	  the	  Gene	  database	  allowed	  us	  to	  identify	  a	  previously	  undescribed	  variant	  (XM_011518630)	  that	  contains	  a	  novel	  alternatively	  spliced	  exon	  containing	  a	  stop	  codon	  (exon	  18	  in	  Table	  3	  and	  Figure	  2).	   	  This	  variant	  contains	  the	  alternatively	  spliced	  exons	  11-­‐17,	  and	  therefore	  would	  be	  predicted	  to	  encode	  a	  protein	  with	  a	  long	  FNIII-­‐repeat	  domain,	  but	  would	  lack	  completely	   the	   fibrinogen-­‐like	   globe	   domain.	   	   The	   FBG	   domain	   is	   important	   for	   proteoglycan	   and	  integrin	  binding	  [95,96].	  It	  has	  also	  been	  suggested	  that	  the	  tenascin-­‐C	  FBG	  domain	  can	  activate	  TLR4,	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although	   it	   is	  not	  known	  whether	   this	   is	  a	  direct	  effect	   [97].	   It	  will	   therefore	  be	  of	   interest	   to	   further	  investigate	  the	  expression	  and	  function	  of	  this	  novel	  TNC	  variant.	  	  Physiologically,	   there	   is	   strong	   evidence	   that	   the	   expression	   of	   alternative	   TNC	   splice	   variants	   is	  developmentally	  regulated	  and	  tissue-­‐specific	  [90].	  Furthermore,	  RNA	  seq	  data	  from	  the	  Illumina	  Body	  Map	  project	  suggests	  that	  the	  long	  TNC-­‐001	  variant	  is	  detected	  in	  lung,	  colon	  and	  lymph	  tissues,	  while	  the	   short	   TNC-­‐012	   variant	   is	   detected	   in	   breast,	   ovary	   and	   prostate	   tissue	   (accessed	   via	   ENSEMBL,	  March	  2016).	  	  There	  have	  also	  been	  a	  large	  number	  of	  studies	  suggesting	  that	  in	  particular	  the	  long	  TNC	  isoforms	  are	  associated	  with	  many	  different	  types	  of	  cancer,	  though	  this	  may	  depend	  on	  tumour	  type.	  	  A	  study	  by	  Borsi	  et	  al	  demonstrated	  that	  expression	  of	  long	  variants	  that	  include	  the	  alternatively	  spliced	  region	  was	  associated	  with	  high	  stromal	  cellularity	  [98].	  More	  recent	  studies	  using	  antibodies	  specific	  for	  the	  alternatively	  spliced	  regions	  have	  shown	  that	  TNC	  variants	  containing	  these	  regions	  are	  absent	  in	   normal	   tissue	   but	   expressed	   at	   the	   tumour	   invasion	   front	   and	   are	   associated	  with	  metastasis.	   For	  example,	   a	   TNC	   antibody	   specific	   to	   exon	   14	   detected	   a	   high	  molecular	  weight	   isoform	   in	   basement	  membranes	   and	   stromal	   fibroblasts	   of	   breast	   cancer	   as	  well	   as	   around	   the	   vasculature.	   This	   isoform	  was	   strongly	   expressed	   in	   the	   stroma	  of	  highly	   invasive	  breast	   tissues	  but	  was	   largely	  undetected	   in	  benign	  and	  normal	   tissue	   [99].	   Similarly,	   antibodies	  with	  high	  affinity	   for	   the	   spliced	   region	  detected	  strong	   expression	   of	   large	   TNC	   variants	   in	   high	   grade	   astrocytomas,	   particularly	   near	   vascular	  structures	   and	   proliferating	   cells	   [100].	   There	   is	   currently	   widespread	   interest	   in	   using	   the	   tumour	  specific	  expression	  of	  TNC	  variants	  to	  target	  anti-­‐cancer	  therapies,	  and	  growing	  interest	  in	  developing	  variant-­‐specific	  TNC	  antagonists	  [90].	  
	  
Functional	  and	  clinical	  significance	  of	  periostin	  splice	  variants	  Periostin	   is	   encoded	   by	   the	   POSTN	   gene	   on	   human	   chromosome	   13.	   Similar	   to	   osteopontin	   and	  tenascin-­‐C,	  periostin	  binds	  a	  number	  of	  integrins	  and	  regulates	  cell	  adhesion	  and	  migration	  [101,102].	  	  Periostin	  is	  also	  a	  marker	  of	  tumour	  progression	  in	  many	  types	  of	  human	  cancer,	  including	  pancreatic,	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ovarian,	   and	   breast	   carcinomas,	   and	   is	   thought	   to	   promote	   a	   tumour-­‐supportive	   microenvironment	  	  [101,103,104].	  	  	  Nine	  POSTN	  splice	  variants	  are	  identified	  in	  ENSEMBL	  and	  Gene	  databases,	  as	  detailed	  in	  Table	  4	  (the	  naming	   of	   isoforms	   used	   by	   Morra	   et	   al	   is	   used	   throughout	   the	   text	   for	   simplicity)	   [18,105].	   The	  Periostin	  protein	  includes	  four	  fasciclin-­‐like	  1	  (FAS-­‐1)	  repeats	  that	  mediate	  integrin	  binding,	  as	  shown	  in	   Figure	   3.	   	   Alternatively	   splicing	   exclusively	   affects	   the	   C-­‐terminal	   region	   that	   has	   no	   known	  conserved	   functional	   domains	   and	   appears	   to	   be	   intrinsically	   disordered.	   	   The	   functional	   effect	   of	  alternative	  splicing	  is	  therefore	  difficult	  to	  predict.	  	  Hoersch	  et	  al	  investigated	  diversity	  and	  isoforms	  of	  periostin	   from	   an	   evolutionary	   perspective,	   and	   hypothesized	   that	   the	   C’	   domain,	   while	   lacking	   in	  known	  functional	  domains,	  may	  assume	  a	  structure	  of	  multiple	  consecutive	  beta	  strands	  when	  binding	  to	   sequential	  beta	   strand	  elements	  of	   fibronectin	  domains	   [106].	   	  This	   region	  does,	  however,	   contain	  predicted	  heparin	  binding	  domains	   and	   also	   an	   anomalous	  nuclear	   localisation	   signal	   [106,107].	   The	  periostin	   C-­‐terminal	   region	   is	   also	   thought	   to	   regulate	   cell–matrix	   interactions	   through	   binding	   of	  additional	  ECM	  proteins	  such	  as	  collagen,	  fibronectin	  and	  tenascin-­‐C	  [108].	  Interestingly,	  TGFβ	  induced	  protein	  (TGFβIp)	  is	  a	  paralog	  of	  periostin	  that	  has	  the	  same	  domain	  structure	  except	  for	  the	  absence	  of	  this	  C’	  region	  [109-­‐111].	  Similarly,	  the	  Drosophila	  protein	  midline	  fasciclin	  (MFAS)	  is	  also	  classified	  as	  a	  periostin	   homologue	   and	   also	   lacks	   this	   C’	   region,	   although	   is	   alternatively	   spliced	   at	   its	   unique	   N’	  domain	  [112].	  Furthermore,	  the	  capacity	  of	  periostin	  to	  regulate	  invasiveness	  and	  lung	  metastasis	  also	  maps	   to	   the	  C-­‐terminus	  of	   the	  protein	   [113,114],	   supporting	   the	   functional	  significance	  of	  alternative	  splice	  variants.	  	  	  	  Periostin	  splice	  variant	  expression	  is	  regulated	  during	  development	  in	  multiple	  tissues,	  with	  additional	  isoforms	   expressed	   during	   foetal	   development	   in	   both	   lung	   and	   kidney	   [105].	   Tissue-­‐specific	  expression	  has	  also	  been	  observed,	  with	  isoform	  6	  detected	  in	  renal	  but	  not	  lung	  tissue	  [105].	  Multiple	  isoforms	  were	  also	  identified	  in	  normal	  adult	  kidney	  (isoforms	  3,	  5	  and	  8).	  	  Interestingly,	  isoform	  8	  was	  detected	   more	   frequently	   in	   renal	   cell	   carcinoma	   than	   in	   matched	   normal	   tissue	   [18].	   	   Of	   the	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alternatively	  spliced	  exons	  17-­‐21,	  this	  isoform	  contains	  exon	  20	  alone.	  Since	  only	  the	  C-­‐terminal	  exons	  14	   to	   23	  were	   examined	   this	   isoform	   remains	   to	   be	   fully	   characterised,	   and	   it	   remains	   to	   be	   shown	  whether	  this	  isoform	  produces	  a	  functional	  protein.	  	  Multiple	  periostin	  isoforms	  were	  also	  identified	  in	  thyroid	  carcinoma,	  but	  expression	  was	  not	  different	  to	  normal	  tissue	  [115].	  	  In	  support	  of	  highly	  tissue	  specific	  expression	  patterns,	  the	  RNA	  seq	  data	  in	  ENSEMBL	  suggests	  that	  while	  isoform	  1	  is	  expressed	  in	   breast,	   ovary,	   testes	   and	  heart	   tissue,	   isoform	  3	   is	   expressed	   in	   adipose,	   colon,	   kidney,	   lymph	  and	  prostate,	   isoform	   5	   is	   expressed	   in	   the	   thyroid,	   while	   the	   novel	   isoform	   POSTN-­‐003	   is	   expressed	   in	  adrenal	  tissues	  (ENSEMBL	  accessed	  March	  2016).	  	  	  Although	  periostin	  is	  frequently	  overexpressed	  in	  different	  cancers,	  periostin	  mRNA	  is	  downregulated	  in	   bladder	   cancer.	   	   Kim	   et	   al	   showed	   that	   normal	   bladder	   tissues	   expressed	   four	   different	   periostin	  splice	  variants,	  corresponding	  to	  isoforms	  1,	  2,	  3	  and	  4	  [114].	  	  The	  normal	  bladder	  therefore	  expresses	  a	  distinct	  splice	  variant	  prolife	  to	  the	  normal	  kidney.	  	  Importantly,	  all	  bladder	  cancer	  tissues	  examined	  had	   lost	   expression	  of	   the	   full	   length	  mRNA	   (isoform	  1),	   and	  48%	  of	   bladder	   cancer	   tissues	  had	   lost	  expression	  of	   alternatively	   spliced	  versions	  of	   periostin.	   	   Instead,	   Isoform	  4	  was	   the	  most	   commonly	  expressed	  periostin	  variant	  in	  bladder	  cancer	  tissues.	  Functional	  analysis	  showed	  that	  this	  variant	  lacks	  the	  capacity	  to	  inhibit	  cell	  invasion	  and	  metastasis	  that	  were	  observed	  for	  both	  isoforms	  1	  and	  3.	  	  This	  suggests	  that	  a	  shift	  from	  full	  length	  to	  alternatively	  splice	  variants	  of	  periostin	  may	  be	  involved	  in	  the	  metastasis	  of	  bladder	  cancer	  [114].	  Isoform	  4	  contains	  only	  exons	  19	  and	  20	  of	  the	  alternatively	  spliced	  exons,	   and	   like	   Isoform	   8	   that	   is	   associated	   with	   renal	   cell	   carcinoma,	   this	   isoform	   may	   also	   lack	  important	  functional	  domains.	  	  	  However,	   further	   studies	   are	   needed	   to	   more	   fully	   characterise	   periostin	   splice	   variants.	   Of	   the	   9	  potential	  splice	  variants	  identified	  in	  the	  databases,	  only	  four	  have	  been	  fully	  sequenced	  and	  studied	  in	  some	  detail	   [18].	   Analysis	   of	   the	   predicted	   proteins	   encoded	   by	   all	   variants	   is	   currently	   lacking,	   and	  further	   work	   is	   needed	   to	   investigate,	   for	   example,	   whether	   the	   predicted	   protein	   coding	   periostin	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isoforms	   indeed	   produce	   functional	   proteins,	   and	   how	   binding	   to	   collagen	   and	   other	   matricellular	  components	  is	  affected	  in	  these	  isoforms.	  	  	  	  
Perspectives	  and	  conclusions	  There	   are	   interesting	   parallels	   between	   the	   regions	   affected	   by	   alternative	   splicing	   in	   periostin	   and	  osteopontin.	   	   Both	   are	   regions	   lacking	   in	   conserved	   functional	   domains	   [65,106].	   Furthermore,	   both	  spliced	   domains	   are	   thought	   to	   contain	   heparin-­‐binding	   sites	   that	   mediate	   matrix	   binding	  [18,26,106,107].	   This	   suggests	   that	   alternative	   splicing	   in	   these	   matricellular	   proteins	   produces	  variants	   with	   altered	   matrix	   binding	   properties;	   although	   this	   will	   require	   experimental	   testing	   to	  substantiate.	   Interestingly,	   the	   correspondence	  between	  alternatively	   spliced	  exons	  and	  unstructured	  proteins	  or	  regions,	  rather	  than	  in	  a	  globular	  domain,	  is	  consistent	  with	  current	  thinking	  in	  terms	  of	  the	  tolerance	  of	  protein	  structures	  to	  accommodate	  variation.	  	  It	  has	  been	  observed	  that	  splicing	  is	  coupled	  with	  protein	  disorder,	   as	   such	  proteins	   are	  naturally	   less	   prone	   to	  mis-­‐folding	   and	  degradation	   [52].	  	  However,	   this	   is	   not	   exclusively	   the	   case,	   and	   around	   28%	   alternatively	   spliced	   variants	   have	   split	  protein	   domains	   [52].	   For	   tenascin-­‐C,	   although	   the	   complete	   structure	   of	   this	   large	   protein	   is	   not	  known,	   the	   structure	  must	   allow	   for	   variable	  FNIII	   repeat	  numbers.	   	   Protein	   repeats	   can	   form	  either	  open	  or	  closed	  structures,	  and	  open	  structures	  tend	  to	  be	  more	  tolerant	  of	  variable	  copy	  number	  [116],	  suggesting	  that	  the	  tenascin-­‐C	  FNIII	  repeats	  may	  form	  an	  open	  structure.	  	  We	   have	   identified	   that	   the	   protein	   encoded	   by	   the	   recently	   described	  OPN-­‐5	   isoform	   lacks	   a	   signal	  peptide	   and	   is	   therefore	   likely	   to	   be	   located	   intracellularly.	   Intracellular	   osteopontin	   is	   important	   in	  innate	  immune	  cells,	  yet	  was	  previously	  thought	  not	  to	  occur	  as	  a	  result	  of	  alternative	  splicing	  (80).	  It	  will	  therefore	  be	  important	  to	  test	  the	  expression	  of	  OPN-­‐5	  in	  innate	  immune	  cells.	  	  Similarly,	  the	  study	  of	   splice	   variants	   of	   other	   matricellular	   proteins	   may	   also	   identify	   novel	   intracellular	   variants,	   and	  therefore	   provide	   an	   alternative	   explanation	   of	   the	   intracellular	   staining	   pattern	   observed	   for	  many	  matricellular	   proteins	   [117].	   	   Endocytosis	   from	   the	   extracellular	   environment	   has	   been	   observed	   for	  some	   matricellular	   proteins	   and	   is	   currently	   thought	   to	   be	   responsible	   for	   the	   presence	   of	   these	  
	   20	  
particular	   matricellular	   proteins	   within	   the	   cell.	   	   For	   example,	   there	   is	   evidence	   that	   SPARC	   is	  endocytosed	   from	   the	   extracellular	   environment	   and	   subsequently	   present	   in	   both	   cytoplasm	   and	  associated	  with	  the	  nuclear	  matrix	  [118].	  	  A	  similar	  mechanism	  of	  internalisation	  into	  the	  cytoplasm	  via	  an	   endosomal	   pathway	   has	   also	   been	   described	   for	   CTGF	   (CCN2)	   [119,120].	   However,	   it	   remains	  possible	  that	  intracellular	  splice	  variants	  are	  also	  expressed	  for	  these	  or	  other	  matricellular	  proteins.	  	  	  For	  the	  matricellular	  proteins	  osteopontin,	  tenascin-­‐C	  and	  periostin,	  there	  is	  clear	  evidence	  for	  tissue-­‐specific	  expression	  of	  multiple	  splice	  variants,	  and	  growing	  interest	  in	  their	  clinical	  significance	  as	  both	  prognostic	  markers	   and	   therapeutic	   targets.	   In	   particular,	   identification	   of	   tenascin-­‐C	   splice	   variants	  with	  opposing	  functions	  has	  helped	  to	  resolve	  controversy	  over	  the	  role	  of	  this	  protein	  in	  cell	  adhesion.	  	  The	   identification	   of	   splice	   variants	   for	   the	  majority	   of	  matricellular	   proteins	   in	   ENSEMBL	   and	  Gene	  databases	   suggests	   that	   further	   research	   into	   potential	   matricellular	   splice	   variants	   is	   warranted.	  	  However,	   dissecting	   the	   diversity	   of	   splice	   variants	   and	   their	   functional	   significance	   is	   challenging.	  	  Often,	  multiple	  matricellular	  isoforms	  are	  detected	  at	  the	  protein	  level	  using	  traditional	  techniques	  such	  as	  western	  blotting,	  but	  it	  can	  be	  difficult	  to	  decipher	  splice	  variants	  from	  isoforms	  resulting	  from	  post-­‐translational	   modifications	   and	   enzymatic	   cleavage.	   Furthermore,	   splice	   variants	   themselves	   are	  subject	   to	   additional	   post-­‐translational	   modifications,	   and	   may	   not	   even	   be	   detected	   by	   existing	  antibodies.	  	  Proteomics	  techniques	  such	  as	  mass	  spectrometry	  analysed	  in	  the	  context	  of	  tissue-­‐specific	  alternative	   transcript	  databases	  will	  be	  required	   to	  determine	   the	  degree	   to	  which	  splice	  variation	  at	  the	  transcript	  level	  is	  reflected	  at	  the	  protein	  level.	  	   	  In	  addition,	  the	  effect	  of	  variants	  affecting	  5’-­‐	  and	  3’-­‐UTR	  regions	  are	  likely	  to	  be	  reflected	  in	  changes	  in	  protein	  abundance	  rather	  than	  protein	  sequence.	  	  However,	  despite	  these	  challenges,	  we	  suggest	  that	  embracing	  the	  complexity	  of	  matricellular	  protein	  splice	   variation	   will	   be	   an	   important	   step	   towards	   more	   fully	   understanding	   their	   function	   and	   for	  effective	  clinical	  application	  of	  these	  powerful	  regulatory	  proteins.	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Figure	  and	  Table	  legends	  	  
Figure	   1:	  Alternative	   splicing	   of	   the	   human	   osteopontin	   gene	   (SPP-­1)	   and	   associated	   protein	  
domains.	  (A)	  The	  osteopontin	  (OPN)	  protein	  is	  relatively	  unstructured	  and	  lacks	  conserved	  domains.	  Instead,	  the	  regions	  involved	  in	  ligand	  binding	  are	  indicated.	  	  Splicing	  affects	  a	  region	  in	  the	  N-­‐terminal	  region	   of	   the	   protein	   following	   the	   signal	   peptide	   (SP;	   AA	   31-­‐72	   in	   the	   OPN-­‐a	   sequence),	   shown	   in	  orange.	   This	   region	   does	   not	   contain	   any	   known	   ligand	   binding	   domains	   but	   does	   include	   O-­‐linked	  glycosylation	  and	  phosphorylation	  sites	  [26].	  	  There	  are	  also	  three	  integrin-­‐binding	  motifs	  in	  the	  central	  region	  of	  the	  protein,	  plus	  a	  C-­‐terminal	  region	  responsible	  for	  CD44	  binding	  and	  containing	  an	  EF-­‐hand	  calcium	  binding	  motif	   [64].	  The	  site	  of	  Thrombin	  cleavage	  (AA	  169	   in	   the	  OPN-­‐a	  sequence)	   is	  shown,	  and	  OPN	  is	  also	  cleaved	  by	  MMPs	  at	  AA	  166,	  201	  and	  210.	  Heparin	  binding	  sites	  have	  been	  identified	  at	  AA	   151-­‐160	   and	   276-­‐283	   [26,64].	   Diagram	   is	   not	   to	   scale.	   (B)	   The	   ENSEMBL	   database	   identifies	   5	  protein	   coding	   alternative	   transcripts	   for	   the	  SPP-­1	   gene,	   resulting	   from	   the	   alternative	   splicing	   of	   2	  exons	  (blue	  box).	  (C)	  The	  NCBI	  Gene	  database	  also	  identifies	  5	  alternative	  protein	  coding	  transcripts	  for	  
SPP-­1,	   but	   identifies	   an	   additional	   variant	   not	   in	   ENSEMBL	   (‘OPN-­‐5’)	   that	   includes	   a	   novel	   exon	  upstream	   of	   the	   alternatively	   spliced	   exons.	   	   This	   exon	   contains	   an	   alternative	   translation	   start	   site.	  	  Little	  is	  as	  yet	  known	  about	  the	  structure	  or	  function	  of	  this	  variant,	  but	  if	  the	  downstream	  translation	  start	   site	   is	   used	   the	  protein	  would	  be	   expected	   to	  be	  present	   intracellularly	   since	   it	   lacks	   the	   signal	  peptide	   for	   secretion.	   The	   common	   OPN	   variant	   names	   are	   indicated	   in	   (B)	   and	   (C),	   and	   Table	   3	  provides	   an	  overview	  of	   the	  different	   IDs.	  All	   databases	   accessed	   in	  November	  2015.	   (D)	   The	  OPN-­‐5	  transcript	  contains	  an	  upstream	  open	  reading	   frame	  (uORF)	  that	  may	  serve	   to	  regulate	  expression	  of	  the	   downstream	   protein	   coding	   sequence.	   	   The	   presence	   of	   the	   uORF	   also	   implies	   that	   the	   OPN-­‐5	  transcript	  can	  only	  produce	  a	  protein	  lacking	  a	  signal	  peptide,	  as	  discussed	  in	  the	  text.	  	  OPN-­‐a	  is	  shown	  for	  comparison	  (transcripts	  not	  to	  scale).	  	  
Figure	   2:	   Alternative	   splicing	   of	   the	   human	   tenascin-­C	   gene	   (TNC)	   and	   associated	   protein	  
domains.	  (A)	  At	  the	  protein	  level,	  each	  tenascin-­‐C	  monomer	  consists	  of	  a	  signal	  peptide	  targeting	  the	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protein	   for	   secretion	   (SP),	   an	   N’	   terminal	   Tenascin	   Assembly	   (TA)	   domain	   responsible	   for	   hexamer	  formation	  and	  a	  run	  of	  14.5	  Epidermal	  Growth	  Factor-­‐Like	  (EGF-­‐L)	  repeats.	   	  Towards	  the	  C-­‐terminus	  are	  between	  8-­‐17	  Fibronectin	  Type	  III-­‐Like	  (FNIII)	  repeats,	  and	  the	  number	  of	  repeats	  is	  determined	  by	  alternative	  splicing;	  plus	  a	  C-­‐terminal	  Fibrinogen-­‐Like	  Globe	  (FBG)	  domain.	  	  The	  FNIII	  repeats	  shown	  in	  white	  are	  expressed	  in	  all	  variants,	  while	  the	  orange	  boxes	  indicate	  alternatively	  spliced	  FNIII	  repeats.	  Diagram	  is	  not	  to	  scale.	  (B)	  The	  ENSEMBL	  database	  identifies	  6	  alternative	  protein	  coding	  transcripts	  for	   the	  TNC	   gene,	   resulting	   from	   the	   alternative	   splicing	  of	   9	   exons	   towards	   the	  3’	   end	  of	   the	   coding	  sequence	  (blue	  box).	  The	  original	  publication	  by	  Nies	  et	  al	  describing	  the	  human	  TNC	  cDNA	  sequence	  and	  domain	  structure	  was	  used	  to	  identify	  the	  nucleotide	  sequence	  corresponding	  to	  each	  named	  FNIII	  repeat	  and	  identify	  the	  corresponding	  exon	  in	  the	  ENSEMBL	  database	  [121].	  Additional	  splice	  variants	  identified	  in	  the	  NCBI	  Gene	  database	  are	  given	  in	  Table	  3.	  All	  databases	  accessed	  in	  November	  2015.	  	  	  
Figure	   3:	   Alternative	   splicing	   of	   the	   human	   periostin	   gene	   (POSTN)	   and	   associated	   protein	  
domains.	   (A).	   The	   periostin	   protein	   consists	   of	   a	   signal	   peptide	   (SP)	   that	   targets	   the	   protein	   for	  secretion,	  a	  cysteine	  -­‐rich	  EMI	  domain,	  and	  four	  fasciclin-­‐like	  1	  (FAS-­‐1)	  repeats.	  	  The	  second	  and	  fourth	  FAS1	  domains	  contain	  integrin	  binding	  domains	  (black	  diamonds).	   	  The	  alternatively	  spliced	  C’	  region	  (shown	   in	  orange)	  has	  no	  known	  functional	  domains	  and	  appears	   to	  be	   intrinsically	  disordered.	   	  The	  functional	   effect	   of	   alternative	   splicing	   is	   therefore	  difficult	   to	  predict.	   	  However,	   there	   are	  predicted	  heparin	  binding	  domains	   in	   the	  C’	   tail	   (blue	  circle),	  and	  also	  an	  anomalous	  nuclear	   localisation	  signal	  (green	   oval)	   [106,107].	   Diagram	   is	   not	   to	   scale.	   (B).	  The	   ENSEMBL	   database	   identifies	   6	   alternative	  protein	  coding	  transcripts	  for	  POSTN,	  resulting	  from	  the	  alternative	  splicing	  of	  5	  exons	  towards	  the	  3’	  end	  of	  the	  coding	  sequence	  (blue	  box).	  Additional	  splice	  variants	  identified	  in	  the	  NCBI	  Gene	  database	  are	  given	  in	  Table	  4.	  All	  databases	  accessed	  in	  November	  2015.	  	  	  
Table	  1:	  Analysis	  of	  splice	  variants	  of	  matricellular	  genes	  in	  the	  ENSEMBL	  database.	  The	  number	  of	  human	  variants	  for	  the	  main	  matricellular	  proteins	  listed	  in	  the	  ENSEMBL	  database	  (accessed	  August	  2015).	   	  The	  final	  column	  indicates	  the	  number	  of	  variants	  for	  which	  there	  is	  a	  high	  transcript	  support	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level	  (TSL).	  	  TSL1	  is	  the	  highest	  support	  level,	  defined	  as	  when	  transcripts	  are	  supported	  by	  at	  least	  one	  non-­‐suspect	   mRNA.	   CDS	   =	   coding	   sequence.	   Other	   matricellular	   proteins	   not	   listed	   here	   include:	   R-­‐spondins,	   short	   fibulins,	   small	   leucine	   rich	   proteoglycans	   (SLRPs),	   autotaxin,	   pigment	   epithelium	  defived	  factor	  (PEDF)	  and	  plasminogen	  activator	  inhibitor-­‐1	  (PAI-­‐s).	  	  
Table	  2:	  Osteopontin	  variants	  encoded	  by	  the	  SPP-­1	  gene.	  	  The	  splice	  variant	  identifiers	  used	  in	  the	  literature,	   in	  ENSEMBL	  and	  in	  Genbank	  are	  cross-­‐referenced	  and	   the	   alternatively	   spliced	  exons	   in	   each	  variant	   given.	  The	  number	  of	  predicted	  amino	  acids	   (AA)	  and	   the	   transcript	   support	   level	   (TSL)	   from	   the	   ENSEMBL	   database	   are	   also	   indicated.	  Matricellular	  proteins	   undergo	   extensive	   post-­‐translational	   modification	   and	   also	   proteolytic	   cleavage,	   so	   the	  observed	  molecular	  weight	   of	   each	   variant	  may	   not	   correspond	   to	   that	   predicted	   by	   the	   amino	   acid	  sequence.	   	  *Number	  predicted	  amino	  acids	  not	  given	  as	  coding	  sequence	  (CDS)	  is	  incomplete	  at	  the	  3’	  end	  in	  ENSEMBL.	  All	  databases	  accessed	  in	  November	  2015.	  	  	  
Table	  3:	  Tenascin-­C	  splice	  variants	  encoded	  by	  the	  TNC	  gene.	  	  	  See	  the	  legend	  for	  Table	  2	  for	  further	  detail.	  	  
Table	  4:	  Periostin	  splice	  variants	  encoded	  by	  the	  POSTN	  gene.	  See	  the	  legend	  for	  Table	  2	  for	  further	  detail.	  	  The	  common	  names	  used	  in	  Morra	  et	  al	  [18]	  and	  Kim	  et	  al	  
[114]	  are	  also	  given.	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AA	   TSL	   Genbank	  ID	  
Exons	  present	  in	  
alterna>vely	  
spliced	  region	  
OPN-­‐a	   001	   314	   1	   NM_001040058	   5,	  6	  
OPN-­‐b	   002	   300	   1	   NM_000582	   5	  
OPN-­‐c	   003	   287	   1	   NM_001040060	   6	  
OPN-­‐4	   010	   *	   2	   NM_001251829	  
OPN-­‐5	   -­‐	   -­‐	   -­‐	   NM_001251830	   4,	  5,	  6	  




AA	   TSL	   Genbank	  ID	  
Exons	  present	  in	  alterna>vely	  
spliced	  region	  
TNC-­‐001	   2201	   1	   NM_002160	   11-­‐16	  
TNC-­‐201	   1838	   5	   XM_006717098	   11,	  16,	  17,	  20	  
TNC-­‐011	   2019	   5	   XM_006717098	   11,	  12,	  13,	  15,	  16,	  20	  
TNC-­‐009	   1928	   1	   XM_006717100	   11-­‐15	  
TNC-­‐007	   1838	   1	   XM_006717098	   11,	  16,	  17,	  20	  
TNC-­‐012	   1564	   5	   XM_005251975	   11	  
-­‐	   XM_005251974	   11,	  20	  
-­‐	   XM_011518629	   11,16,20	  
-­‐	   XM_011518626	   11,	  16,	  17,	  19,	  20	  
-­‐	   XM_011518624	   11,	  12,	  15,	  16,	  17,	  19,	  20	  
-­‐	   XM_006717101	   11,	  12	  
-­‐	   XM_011518628	   11-­‐13	  
-­‐	   XM_006717097	   11,	  12,	  13,	  15,	  16,	  19,	  20	  
-­‐	   XM_011518623	   11,	  12,	  13,	  15,	  16,	  17,	  19,	  20	  
-­‐	   XM_005251973	   11-­‐14	  
-­‐	   XM_011518625	   11-­‐16	  
-­‐	   XM_005251972	   11-­‐16,	  20	  
-­‐	   XM_011518622	   11-­‐17,	  20	  
-­‐	   XM_006717096	   11-­‐17,	  19,	  20	  






	  (Kim,	  2008)	  
ENSEMBL	  
variant	  
AA	   TSL	   Genbank	  ID	  
Exons	  present	  in	  
alterna>vely	  
spliced	  region	  
“isoform	  1”	   “WT”	   POSTN-­‐001	   836	   1	   NM_006475	   17-­‐21	  
“isoform	  3	   “variant	  II”	   POSTN-­‐201	   781	   1	   NM_001136935	   18,	  19,	  20	  
POSTN-­‐003	   809	   1	   NM_001286665	   18-­‐21	  
“isoform	  7”	   POSTN-­‐202	   749	   1	   NM_001286666	   20,	  21	  
“isoform	  2”	   “variant	  III”	   POSTN-­‐002	   779	   1	   NM_001135934	   19,	  20,	  21	  
“isoform	  5”	   POSTN-­‐004	   808	   5	   XM_005266231	   17-­‐20	  
“isoform	  4”	   “variant	  I”	   -­‐	   NM_001135936	   19,	  20	  
“isoform	  8”	   -­‐	   NM_001286667	   20	  
“isoform	  6”	   -­‐	   XM_005266232	   17,	  19,	  20,	  21	  
